Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-07-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2023年第二次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, procedures, attendance, voting, and legality of a specific shareholders' meeting, namely the 2023 second extraordinary general meeting of Shenzhen Haier Bioengineering Co., Ltd. It details the legal compliance of the meeting's call, conduct, voting procedures, and results. The document does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not a notice of voting results but a legal opinion on the meeting's legality. Given the nature of the document as a legal opinion on a shareholders' meeting, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length (5123 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is RNS with high confidence.
2023-07-31 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, voting methods, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or detailed report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2023-07-31 Chinese
关于筹划重大事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of planning a major transaction. It repeatedly mentions that no formal agreement has been signed yet and that the company will continue to disclose information as the matter progresses. The document references previous announcements about the planning of major matters and emphasizes risk warnings and compliance with disclosure obligations. The content is focused on the progress update of a significant corporate event, specifically a major asset restructuring and mixed-ownership reform, but does not contain financial statements or detailed financial data. It is not a full report, earnings release, or management discussion. The document is a progress announcement about a major transaction, which fits best under the category of Capital/Financing Update (CAP). The document length is short (1711 characters), and it is not merely announcing the publication of a report but providing substantive update information on the transaction progress. Therefore, the classification is CAP with high confidence.
2023-07-28 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiaries. It lists numerous guarantee contracts with banks and financial institutions, specifying amounts, terms, and conditions. The document is an official disclosure about the company's guarantee activities to support subsidiaries' financing needs. It does not contain financial statements, audit opinions, or management discussions of financial results. It is not a report like an annual or interim report, nor is it a call transcript or a presentation. It is a regulatory announcement about financing guarantees, which fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed guarantee information, not just a brief notice or a certification, so it is not RNS or RPA. Therefore, the classification is CAP with high confidence.
2023-07-28 Chinese
关于2023年度提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of financial assistance to its subsidiaries and related parties. It includes specifics about the financial assistance amounts, terms, risk analysis, and approvals by the board and independent directors. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about financing activities, specifically about providing financial support to subsidiaries, which fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters and contains substantive details about the financing arrangements, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2023-07-14 Chinese
独立董事关于第九届董事局第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding specific board meeting matters, including related party loans and financial assistance to subsidiaries. It references compliance with stock exchange regulations and company bylaws, and it is a formal statement of approval and opinion on these matters. The content focuses on governance and board-level decisions rather than financial results, audit findings, or shareholder voting outcomes. The document length is short (950 characters), and it is not a report or announcement of a report publication. It is not a certification or legal proceeding update. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2023-07-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.